- News & Media
- Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses
- News
- Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal
- Azafaros strengthens leadership team with appointment of Amy Sullivan as Chief Financial Officer
- Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis
- Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 2026
- Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference
- Azafaros further strengthens its Board of Directors with appointment of biotech entrepreneur, Dr. Thierry Abribat
- Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
- Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
- Azafaros Secures € 132M in Oversubscribed Series B Financing to advance Phase 3 clinical programs of innovative therapies in lysosomal storage disorders
- Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
- Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025
- Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 2025
- Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference
- Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C
- Azafaros announces promotion of Dr Anke Arnold-Tugulu to Chief Regulatory Officer
- Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
- Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium
- Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled
- Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients
- Azafaros Appoints Chief Operating Officer and Head of Finance
- Beyond Biotech podcast 35: Rare Disease Day
- Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA
- Azafaros Strengthens Medical and Scientific Management Team Reflecting Clinical Progress
- BREAKING NEWS: Azafaros Receives FDA’s IND Clearance and Fast Track Designation
- Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease
- Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference
- Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis
- Azafaros Announces Multiple Presentations at 18th Annual WORLDSymposium™
- Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer
- Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorders
- Azafaros expands executive management team and operations
- Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline
- Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders
- Azafaros to Present at BIO International Convention 2026
- Media
- Clinical Studies